Cowen & Co. analyst Ritu Baral maintained a Buy rating on Trevena Inc (NASDAQ: TRVN) today and set a price target of $10. The company’s shares opened today at $2.30.
According to TipRanks.com, Baral is a top 25 analyst with an average return of 33.4% and a 55.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
Currently, the analyst consensus on Trevena Inc is Moderate Buy and the average price target is $6, representing a 160.9% upside.
In a report issued on May 3, Oppenheimer also maintained a Buy rating on the stock with a $5 price target.
Find more picks by Best Performing Analysts >>
Based on Trevena Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $9.02 million. In comparison, last year the company had a GAAP net loss of $20.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trevena, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of healthcare services and development of therapies. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A.
